Xla 1
Alternative Names: Xla1; Yso1Latest Information Update: 28 Dec 2023
At a glance
- Originator YSOPIA Bioscience
- Class Bacteria; Obesity therapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Metabolic disorders; Obesity
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Metabolic-disorders(In volunteers) in USA (PO, Capsule)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Obesity(In volunteers) in USA (PO, Capsule)
- 11 Jan 2022 Phase-II clinical trials in Metabolic disorders (PO) (YSOPIA Bioscience pipeline, January 2022)